



The International Bone & Mineral Society (IBMS) Announces The Gideon and Sevgi Rodan IBMS Fellowship

Throughout their productive careers, Gideon Rodan, M.D., Ph.D. and his wife and frequent collaborator Sevgi Rodan, Ph.D. made outstanding contributions to the field of bone biology, including: the isolation and characterization of the first transformed osteoblastic cell line (ROS 17/2.8), the unraveling of the PTH signal transduction mechanisms, the development of the concept of osteoblast-osteoclast interaction, the identification and characterization of integrin antagonists as osteoclast inhibitors, the development of the blockbuster drug Alendronate (Fosamax), and the cloning of alkaline phosphatase.

Both scientists worked for many years in the Department of Bone Biology and Osteoporosis Research at Merck & Company, and both have been leaders in several bone-related organizations. Gideon served as President of the International Bone and Mineral Society from 2001 to 2003.

The Rodans have served as role models and mentors for hundreds of young scientists in the bone field, and IBMS is pleased recognize their many contributions through The Gideon and Sevgi Rodan IBMS Fellowship.

Purpose

The Rodans' Fellowship will be given annually to support the salary of a deserving young investigator in the bone field. Support will be \$40,000 for one year, not renewable, payable to the successful applicant's institution. No overhead may be paid from the fellowship. The research may be basic, translational, clinical, or outcomes-based in bone biology or diseases of the bone.

Eligibility

The fellowship must be held in an academic institution—for example, a medical school, hospital, or research institute; Both Applicant and the Head of the recipient laboratory must be members of IBMS; Applicant must be a Fellow within three years of completing either a doctoral degree (M.D., Ph.D., D.D.S.) or must have carried out equivalent research in basic or clinical bone biology for up to six years since their first degree (M.B.B.S, B.D.Sc, B.Vet Sc etc); A high standard of research achievement for this career stage, with publications and presentations.

Review

In accessing the application, the following will be taken into account:

- ❖ The number and quality of research projects completed or currently engaged in, and the extent of the applicant's personal contribution to such research;
- ❖ Evidence of innovation or leadership in the applicant's research career to the present time;
- ❖ Evidence in the application of particular novelty or initiative on the part of the applicant. For example preference may be given to an applicant who is either moving to a new laboratory or proposing a period of research in another laboratory, either to achieve progress in a specific project or to learn a technique;
- ❖ Success in competitive scholarship or fellowship applications and in competitive peer-reviewed grant applications;
- ❖ Evidence of communication skills in oral presentations.

Application Format

Applications may be submitted by email, fax or sent to IBMS Headquarters directly. Applicants should submit a description of the research proposal on which the award would be spent, and the benefits to be obtained from the year's independent postdoctoral salary. This should be no more than four pages, excluding references. The candidate's curriculum vitae must be also included, as well as a supporting letter from a mentor.

Rating Process

Submissions will be reviewed by the IBMS Awards Committee and rated according to the record of the candidate academically and according to the above criteria, as well as to the scientific value of the proposed project. Up to two (applicant – nominated) referees may be consulted. The final decision will be made by the IBMS Executive Committee.

Award and Funding Process

The 2007 Fellowship will be presented at the 17th Scientific Meeting of the IBMS in Montreal, Canada, June 2007 and will be funded January 2008.

Deadline

Application deadline for 2007 Fellowship – 16 April 2007.

Funding is made possible through the generous support of Merck & Co., Inc.